tetano
Editor, Senior Moderator
J Immunol
. 2022 Aug 1;ji2100968.
doi: 10.4049/jimmunol.2100968. Online ahead of print.
Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries
Yi Luan[SUP] 1 [/SUP], Qianying Yuan[SUP] 1 [/SUP], Qijun Wang[SUP] 1 [/SUP], Susan Compton[SUP] 2 [/SUP], Dianqing Wu[SUP] 3 [/SUP], Wenwen Tang[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2, responsible for the severe acute respiratory syndrome known as COVID-19, has rapidly spread in almost every country and devastated the global economy and health care system. Lung injury is an early disease manifestation believed to be a major contributor to short- and long-term pathological consequences of COVID-19, and thus drug discovery aiming to ameliorate lung injury could be a potential strategy to treat COVID-19 patients. By inducing a severe acute respiratory syndrome-like pulmonary disease model through infecting A/J mice with murine hepatitis virus strain 1 (MHV-1), we show that i.v. administration of pazopanib ameliorates acute lung injuries without affecting MHV-1 replication. Pazopanib reduces cell apoptosis in MHV-1-infected lungs. Furthermore, we also identified that pazopanib has to be given no later than 48 h after the virus infection without compromising the therapeutic effect. Our study provides a potential treatment for coronavirus-induced lung injuries and support for further evaluation of pazopanib in COVID-19 patients.
. 2022 Aug 1;ji2100968.
doi: 10.4049/jimmunol.2100968. Online ahead of print.
Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries
Yi Luan[SUP] 1 [/SUP], Qianying Yuan[SUP] 1 [/SUP], Qijun Wang[SUP] 1 [/SUP], Susan Compton[SUP] 2 [/SUP], Dianqing Wu[SUP] 3 [/SUP], Wenwen Tang[SUP] 3 [/SUP]
Affiliations
- PMID: 35914834
- DOI: 10.4049/jimmunol.2100968
Abstract
Severe acute respiratory syndrome coronavirus 2, responsible for the severe acute respiratory syndrome known as COVID-19, has rapidly spread in almost every country and devastated the global economy and health care system. Lung injury is an early disease manifestation believed to be a major contributor to short- and long-term pathological consequences of COVID-19, and thus drug discovery aiming to ameliorate lung injury could be a potential strategy to treat COVID-19 patients. By inducing a severe acute respiratory syndrome-like pulmonary disease model through infecting A/J mice with murine hepatitis virus strain 1 (MHV-1), we show that i.v. administration of pazopanib ameliorates acute lung injuries without affecting MHV-1 replication. Pazopanib reduces cell apoptosis in MHV-1-infected lungs. Furthermore, we also identified that pazopanib has to be given no later than 48 h after the virus infection without compromising the therapeutic effect. Our study provides a potential treatment for coronavirus-induced lung injuries and support for further evaluation of pazopanib in COVID-19 patients.